Please login to the form below

Not currently logged in
Email:
Password:

Vanda Pharmaceuticals

This page shows the latest Vanda Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

BMS' Opdivo backed as melanoma therapy in EU

BMS' Opdivo backed as melanoma therapy in EU

Vanda Pharmaceuticals got the go-ahead for Hetlioz (tasimelteon) for the treatment of non-24-hour sleep wake disorder in totally blind adults - which was approved in the US last year -

Latest news

  • FDA approves sleep disorder drug for blind people FDA approves sleep disorder drug for blind people

    FDA approves sleep disorder drug for blind people. Vanda Pharmaceuticals wins backing for Hetlioz to improve a person’ s body clock. ... Vanda Pharmaceuticals is now allowed to market its drug Hetlioz (tasimelteon) to treat a condition called

  • FDA panel backs sleep pattern drug for blind FDA panel backs sleep pattern drug for blind

    A Food Drug and Administration (FDA) advisory committee voted unanimously to recommend approval of Vanda Pharmaceuticals' Hetlioz (tasimelteon) for non-24-hour disorder (N24) in the totally blind. ... in 2010.Vanda withdrew a marketing application for

  • Vanda withdraws EU application for schizophrenia drug Vanda withdraws EU application for schizophrenia drug

    Vanda withdraws EU application for schizophrenia drug. CHMP had previously refused to back the approval of Fanaptum. ... Vanda Pharmaceuticals has decided to withdraw its EU marketing application for the use of Fanaptum to treat schizophrenia.

  • Pharma deals for April 2012 Pharma deals for April 2012

    200. Eli Lilly / Vanda Pharmaceuticals. Licence. VLY-686 (NK-1R) antagonist as novel therapeutic in alcohol dependence or to treat CINV / PONV. ... 80. Atlantis Pharma / Valeant Pharmaceuticals. Acquisition. Acquisition of certain products from Mexican

  • FDA starts review of Lundbeck’s antipsychotic aripiprazole

    Novartis and Vanda Pharmaceuticals also have a depot formulation of iloperidone in trials which should reach the market in 2015.

More from news
Approximately 3 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics